WillItSurvive
Pharma and healthcare groups · Australia

Nanosonics

nanosonics.com.au ↗

Makes trophon, the machine hospitals use to disinfect ultrasound probes between patients.

Hard to displace
Assessed 30 July 2026 · Evidence as of 30 July 2026
Strong structural protection; the business model survives ai pressure.
On the recordSince 30 July 2026 · Checkable from August 2026 · Every call on the record Checkpoint: FY26 full-year results release
The call

Nanosonics still owns the hospital workflow for probe disinfection, with cash in the bank and no debt, while its next growth product, CORIS, still has to prove itself in the market.

Nanosonics sells machines called trophon that clean ultrasound probes used by doctors, and it makes most of its money from selling the cleaning liquid and service contracts that keep those machines running. Big competitors like STERIS and Ecolab have tried to copy or replace this business for decades but have not succeeded, because hospitals have built trophon into their daily routines and because regulators require proof that any new system works just as well. The company is also building a new product called CORIS for cleaning endoscopes, which could grow the business, but the real question is whether Olympus, which already partners with Nanosonics, will decide to build its own cleaning machine instead.

Why
01
AI pressure: None apparent. AI doesn't disinfect a probe; the digital tracking layer (AuditPro) could be copied by software, but that's not the core business. Could AI do the core job? Unlikely.
02
Bigger players: Olympus, STERIS, or Getinge building a rival probe or endoscope-channel cleaner. Bigger medtech players could build or buy their way into probe disinfection or endoscope cleaning, but none has a cleared product on the market yet. Could a giant copy it? Probably.
03
What protects it. 25 years of regulatory clearances, 38,080 machines already installed in hospitals, and hospitals locked into buying its consumables to keep using them.
What would change this call
Nanosonics reports H2/FY26 results around 24-25 August 2026. Shows whether revenue growth and margins held versus guidance of $215M-$223M and 75-77% gross margin.
Olympus announces or launches a competing endoscope-channel cleaning product. Would show a major peer moving from partner to direct rival before CORIS gains traction.
CORIS full commercial launch proceeds or slips past targeted FY27. Indicates whether Nanosonics' growth optionality beyond trophon is materializing on schedule.
Key numbers
  • 38,080 trophon units installed worldwide (2025-12-31)
  • Recurring consumables/service revenue up 20% to $146.1M (2025-06-30)
  • Gross margin 76.3%, down from 78.5% on tariffs/freight costs (2025-12-31)
Named risks
  • CORIS full commercial launch, targeted for FY27, could stumble after only entering controlled market release in Feb 2026. Severity: medium
  • Gross margin fell to 76.3% in H1 FY26 from 78.5% prior year on tariffs and airfreight costs. Severity: medium
  • AUD/USD appreciation could cut FY26 revenue guidance by roughly 3% given USD-heavy revenue. Severity: medium
  • Olympus, which dominates GI endoscopes and partners with CORIS, could build or buy a competing channel-cleaning system. Severity: medium
  • Revenue growth decelerated from 17% in FY25 to 9% in H1 FY26. Severity: low
Rivals, as read in July 2026
RivalDirectionEvidence
STERIScontestingAdjacent sterilization giant has not dislodged trophon's installed base over 15+ years as of 2026
GetingecontestingBroad infection-prevention conglomerate competes in adjacent markets, no share taken from trophon as of 2026
OlympuscontestingEcosystem partner for CORIS (indicated for its EVIS EXERA III scopes) but potential future rival if it builds own channel-cleaning tech
EcolabcontestingBroad hygiene/disinfection player named as market participant, no erosion of trophon base reported
TristelcontestingSmaller ultrasound-probe disinfection competitor, installed base still grew to 38,080 units by Dec 2025
Questions people ask
What is the biggest risk to Nanosonics?
The main watch-item is whether CORIS, its endoscope-cleaning product, moves beyond Controlled Market Release toward broader commercialization by 2027-06. Nanosonics's protection comes from its large and growing trophon installed base and the recurring consumables revenue it generates, but this protection depends on that installed base continuing to grow and on CORIS advancing past its current early-release stage.
Is Nanosonics in financial trouble?
No signs of financial trouble appear in the evidence. FY25 profit after tax was A$20.7 million on revenue of A$198.6 million (year ended 2025-06-30), and H1 FY26 revenue reached A$102.2 million, with FY26 guidance set between A$215-223 million to be reported by 2026-08.
Who are Nanosonics's biggest competitors?
In ultrasound probe and scope disinfection, Nanosonics is named alongside Tristel plc and Germitec as device and chemical rivals. Larger sterilization players STERIS plc and Getinge are considered adjacent but have not shipped or announced a competing device into Nanosonics's installed base as of the 2026 assessment.
Is Nanosonics at risk from AI?
AI threat is rated not applicable for Nanosonics. Its business relies on physical hydrogen-peroxide disinfection hardware, and software would sit on top of that hardware rather than replace it, according to the July 2026 assessment.
Could a bigger company like STERIS just copy Nanosonics's product?
This is rated as a possible but distant threat. STERIS plc and Getinge make sterilization equipment but neither has shipped or announced a rival probe or endoscope disinfection system as of the 2026 assessment, and Nanosonics's 38,080 installed trophon units as of 2025-12-31 give it a head start in hospital workflows.
What should I watch to see if Nanosonics stays on track?
Two dated milestones matter: FY26 full-year revenue results expected by 2026-08, measured against guidance of A$215-223 million, and progress on CORIS beyond Controlled Market Release toward wider commercialization by 2027-06. Both are verifiable checkpoints rather than predictions of outcome.
Timeline
  • 2026-03-09CORIS secures first FDA 510(k) clearance to expand indications
  • 2026-03-01National GPO agreement with Premier Inc. for trophon3 takes effect
  • 2026-02-24H1 FY26 results: revenue $102.2M, cash $159.8M, gross margin 76.3%
  • 2026-02-01CORIS controlled market release begins in UK and other markets
  • 2025-11-30AGM approves on-market share buyback of up to $20 million for FY26
  • 2025-08-26FY25 results: revenue $198.6M up 17%, profit after tax $20.7M up 59%
  • 2024-11-30Wireless ultrasound probe holder accessory launched in US and Canada
  • 2024-05-31CORIS system submitted for FDA De Novo classification
  • 2000-11-14Nanosonics Limited incorporated
Revision history
30 July 2026
First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.
In the same band
Vertex PharmaceuticalsTenet HealthcareIntuitive Surgical
More in Pharma and healthcare groups →
Sources